Why we need novel strategies for diffuse large B-cell lymphoma
Debate on the best first-line treatment for unmutated CLL: opinions from across the Atlantic
Panel discussion on large cell lymphomas: subtypes, patient selection and mutations
Andrew Zelenetz et al.
ADCT-402 - a drug to watch
Recognizing the heterogeneity of DLBCL